[HTML][HTML] Whole-genome and transcriptome analysis enhances precision cancer treatment options
E Pleasance, A Bohm, LM Williamson, JMT Nelson… - Annals of …, 2022 - Elsevier
Background Recent advances are enabling delivery of precision genomic medicine to
cancer clinics. While the majority of approaches profile panels of selected genes or hotspot …
cancer clinics. While the majority of approaches profile panels of selected genes or hotspot …
Factors for a Broad Technology Assessment of Comprehensive genomic profiling in Advanced Cancer, a systematic review
LF van Schaik, EG Engelhardt, EA Wilthagen… - Critical reviews in …, 2024 - Elsevier
Abstract Comprehensive Genomic Profiling (CGP) allows for the identification of many
targets. Reimbursement decision-making is, however, challenging because besides the …
targets. Reimbursement decision-making is, however, challenging because besides the …
Long-read sequencing of an advanced cancer cohort resolves rearrangements, unravels haplotypes, and reveals methylation landscapes
Summary The Long-Read Personalized OncoGenomics (POG) dataset comprises a cohort
of 189 patient tumors and 41 matched normal samples sequenced using the Oxford …
of 189 patient tumors and 41 matched normal samples sequenced using the Oxford …
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
HM Witte, J Riedl, A Künstner, A Fähnrich, J Ketzer… - Targeted Oncology, 2023 - Springer
Background There is growing evidence supporting multidisciplinary molecular tumor boards
(MTB) in solid tumors whereas hematologic malignancies remain underrepresented in this …
(MTB) in solid tumors whereas hematologic malignancies remain underrepresented in this …
Primary refractory plasmablastic lymphoma: A precision oncology approach
HM Witte, A Fähnrich, A Künstner, J Riedl… - Frontiers in …, 2023 - frontiersin.org
Introduction Hematologic malignancies are currently underrepresented in multidisciplinary
molecular-tumor-boards (MTB). This study assesses the potential of precision-oncology in …
molecular-tumor-boards (MTB). This study assesses the potential of precision-oncology in …
Group Heteroscedasticity-A Silent Saboteur of Power and False Discovery in RNA-Seq Differential Expression
Despite the availability of several high-profile, state-of-the-art methods, analyzing bulk RNA-
Seq data continues to face significant challenges. Evidence from recent studies has …
Seq data continues to face significant challenges. Evidence from recent studies has …
Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary
RJ Rebello, A Posner, R Dong, OWJ Prall… - medRxiv, 2024 - medrxiv.org
Genomics holds promise for precision treatment and identifying the primary tissue of origin
(TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and …
(TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and …
[HTML][HTML] FKBP5, SLC6A4 Genes as Biomarkers and Treatment Responders in Major Depressive Disorder (MDD)-Treated with Cognitive Behavioral Therapy and …
M Jalalian, M Pourasghar, A Majd, H Ghalehnoei… - IJ Psychiatry and … - brieflands.com
Background: Major depressive disorder is one of the most common causes of disability in
people of the world, so it has imposed a heavy burden on society in terms of medicine and …
people of the world, so it has imposed a heavy burden on society in terms of medicine and …
Analyse coûts-bénéfices du projet Citadelomique cancer de l'ovaire au Centre hospitalier de l'Universitaire [ie Université] de Montréal (CHUM)
BR Aka - 2023 - espace.enap.ca
La prise en charge des patientes atteintes de cancers épithélial de l'ovaire (CEO) à haute
grade séreux (HGS) nécessite la prescription systématiquement d'un traitement d'entretien à …
grade séreux (HGS) nécessite la prescription systématiquement d'un traitement d'entretien à …